- Tytuł:
- 2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience.
- Autorzy:
- Źródło:
- Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 493-500. Date of Electronic Publication: 2024 Jan 09.
- Typ publikacji:
- Journal Article
- MeSH Terms:
-
Carcinoma, Renal Cell*/pathology
Antineoplastic Agents */adverse effects
Kidney Neoplasms*/pathology
Adult ; Humans ; Sunitinib/therapeutic use ; Indoles/adverse effects ; Pyrroles/adverse effects ; Treatment Outcome ;Disease -Free Survival ; Retrospective Studies - SCR Disease Name:
- Clear-cell metastatic renal cell carcinoma
Czasopismo naukowe